ANTIBODIES FOR IL-17C
The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
1 - 15 . (canceled)
16 . A method for treating a subject suffering from cancer, comprising administering to said subject an effective amount of an antibody or antibody fragment specific for IL-17C comprising
(a) a HCDR1 region comprising the amino acid sequence of SEQ ID NO: 7, a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 8, a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 9, a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 13, a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 14 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO: 15, or
(b) a HCDR1 region comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 21, a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 22, a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 26, a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 27 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO: 28, or
(c) a cross-competing antibody or antibody fragment thereof.
17 - 19 . (canceled)
20 . The method of claim 16 , wherein said antibody or antibody fragment comprises
(a) a HCDR1 region of SEQ ID NO: 7, the HCDR2 region of SEQ ID NO: 8, the HCDR3 region of SEQ ID NO: 9, the LCDR1 region of SEQ ID NO: 13, the LCDR2 region of SEQ ID NO: 14 and the LCDR3 region of SEQ ID NO: 15, or
(b) a HCDR1 region of SEQ ID NO: 20, the HCDR2 region of SEQ ID NO: 21, the HCDR3 region of SEQ ID NO: 22, the LCDR1 region of SEQ ID NO: 26, the LCDR2 region of SEQ ID NO: 27 and the LCDR3 region of SEQ ID NO: 28.
21 . The method of claim 16 , wherein said antibody or antibody fragment is specific for human IL-17C.
22 . The method of claim 16 , wherein said antibody or antibody fragment is specific for human IL-17C, cynomolgus IL-17C and mouse IL-17C.
23 . The method of claim 16 , wherein said antibody or antibody fragment is a human, humanized or chimeric antibody or antibody fragment.
24 . The method of claim 16 , wherein said antibody or antibody fragment comprises a heavy chain of SEQ ID NO: 17 and a light chain of SEQ ID NO: 16.
25 . The method of claim 16 , wherein said antibody or antibody fragment comprises a heavy chain of SEQ ID NO: 30 and a light chain of SEQ ID NO: 29.
26 . The method of claim 16 , wherein said antibody or antibody fragment is an isolated antibody or antibody fragment.
27 . The method of claim 16 , wherein said antibody or antibody fragment is a recombinant antibody or antibody fragment.
28 . The method of claim 16 , wherein the subject is administered a pharmaceutical composition comprising said antibody or antibody fragment and a pharmaceutically acceptable carrier or excipient.